TTR and Familial transthyretin-related amyloidosis: In a report from 2021, CRISPR/Cas9-mediated in vivo deletion of transthyretin (TTR), which is mutated in progressively fatal transthyretin amyloidosis, led to a striking decrease of circulating transthyretin protein levels in the peripheral blood of treated patients (191).